InSphero, AstraZeneca Islet Microtissue Work Wins Best Poster Award at EASD Islet Study Group

InSphero, AstraZeneca Islet Microtissue Work Awarded "Best Poster" at EASD Islet Study Group & Beta Cell Workshop

Schlieren, Switzerland - May 9, 2017

InSphero's Burcak Yesildag, PhD and collaborators at AstraZeneca Mölndal were announced on Tuesday, May 9th as winners of the Poster Award at the annual EASD Islet Study Group & Beta Cell Workshop, held in Dresden, Germany.  The poster, entitled "A Novel Standardized In Vitro Islet Model System for Assessment of Pancreatic β-cell Proliferation" is the second such honor for InSphero in 2017, having received the ELRIG Research & Innovation "Best Technology" Award in March for the full portfolio of advanced 3D InSight™ Microtissues for drug safety and efficacy testing.

The scientific program at the annual conference covers a wide spectrum of topics in the field of islet biology, including beta cell development, maturation and regeneration, beta cell function, genetics & epigenetics of beta cells, beta cell therapy and beta cell interaction with immune cells. Attendees include leaders in the field, rising stars as well as postdocs and students, who come together to exchange their latest findings and ideas in order to foster progress and networking in the field of islet biology.  

In addition to May presentations at the European Society for Animal Cell Technology (ESACT) in Lausanne, Switzerland and the Midwest Islet Club (Madison, WI) featuring 3D InSight™ Islet Microtissues, Dr. Yesildag will present groundbreaking work performed in collaboration with the ETH Zurich assessing islet microtissue function under perifusion conditions in a microphyisiological system (MPS) at the 77th Scientific Sessions of the American Diabetes Association (ADA) Meeting held June 9-13 in San Diego, CA.  

 

BYe

Dr. Burcak Yesildag, InSphero AG 

Islet no background

InSphero 3D InSight™ Islet Microtissues provide greater confidence to pharmaceutical drug discovery and development groups in their efforts to better assess diabetes drug efficacy and safety.

Company video

company-video-inspheor